Equity Overview
Price & Market Data
Price: $2.99
Daily Change: -$0.228 / 7.60%
Daily Range: $2.97 - $3.27
Market Cap: $909,978,496
Daily Volume: 4,703,134
Performance Metrics
1 Week: 3.40%
1 Month: -28.97%
3 Months: -16.94%
6 Months: -27.10%
1 Year: -3.18%
YTD: -11.11%
Company Details
Employees: 596
Sector: Health technology
Industry: Biotechnology
Country:
Details
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its product pipeline includes ABCL635, an antibody-drug candidate, which is in preclinical trial to treat metabolic and endocrine conditions; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in preclinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.